Clincosm LogoSign in Get a demo

Immunotherapy Vaccine and Herceptin in Breast Cancer

Sponsor
Cancer Insight, LLC (Industry)
Overall Status
Completed
CT.gov ID
NCT03014076
Collaborator
(none)
30
Enrollment
2
Arms
108
Duration (Months)

Study Details

Study Description

Brief Summary

The purpose of this trial is to determine if combination immunotherapy with HER2/neu GP2 peptide + GM-CSF vaccine and trastuzumab is safe and immunologically effective in treatment of patients with HER2/neu over-expressing breast cancer in the adjuvant setting. While not a primary endpoint, time to recurrence is measured for enrolled subjects. The objectives of the study are the following:

  • Assess safety and document local and systemic toxicity to combination immunotherapy with GP2 peptide + GM-CSF vaccine and trastuzumab

  • Evaluate the in vitro and in vivo immunologic responses to combination immunotherapy of GP2 peptide + GM-CSF vaccine and trastuzumab

  • Determine maximum tolerated dose and optimal biologic dose for the combination immunotherapy of GP2 peptide + GM-CSF vaccine and trastuzumab

Condition or Disease Intervention/Treatment Phase
Phase 1

Study Design

Study Type:
Interventional
Actual Enrollment :
30 participants
Allocation:
Non-Randomized
Intervention Model:
Parallel Assignment
Masking:
None (Open Label)
Primary Purpose:
Treatment
Official Title:
Phase Ib Trial of Combination Immunotherapy With HER2/Neu Peptide GP2 + GM-CSF Vaccine and Trastuzumab in Breast Cancer Patients
Study Start Date :
Jan 1, 2008
Actual Primary Completion Date :
Jan 1, 2016
Actual Study Completion Date :
Jan 1, 2017

Arms and Interventions

Arm Intervention/Treatment
Experimental: GP2 peptide + GM-CSF + trastuzumab

HLA-A2+/A3+ subjects receive GP2 + GM-CSF vaccine and trastzumab

Drug: GP2 peptide + GM-CSF vaccine plus trastuzumab
HLA-A2+/A3+ subjects are given the GP2 peptide vaccine plus trastuzumab
Active Comparator: Trastuzumab

HLA-A2-/A3- subjects followed as controls receiving trastuzumab.

Drug: Trastuzumab
HLA-A2-/A3- patients are followed as controls receiving trastuzumab only.
Other Names:
  • Herceptin

    		•

    Outcome Measures

    Primary Outcome Measures

    1. Treatment-Related Adverse Events as Assessed by CTCAE v4.0 [12 months]

      Patients receiving treatment will be followed from baseline to completion of study for adverse events using CTCAE v4.0

    Eligibility Criteria

    Criteria

    Ages Eligible for Study:
    18 Years and Older
    Sexes Eligible for Study:
    Female
    Accepts Healthy Volunteers:
    Yes
    Inclusion Criteria:

    • Age > 18 years

    • HER2/neu+ over-expressing breast cancer (IHC 3+ or FISH ≥2.0)

    • Patients who are receiving adjuvant trastuzumab as standard of care treatment

    • Completion of breast cancer therapy (i.e., surgery, radiation, and chemotherapy as appropriate per standard of care for patients' specific cancer) to exclude trastuzumab (Patients on oral hormonal therapy as part of their adjuvant breast cancer treatment will be maintained on their regimens.)

    • Enrollment must occur so that patients' trastuzumab treatment and vaccine schedule overlap for all 6 vaccinations and so that first vaccination occurs after a standard of care Multiple Gated Acquisition Scan (MUGA)

    • ECOG performance status (PS) 0-1

    • Clinically cancer-free (no evidence of disease; excluding +CTC)

    • If the patient is of childbearing potential, she must be willing to practice adequate contraception through the study treatment period and for 2 months after completion of the injection sites

    • Ability to understand and the willingness to sign a written informed consent document

    Exclusion Criteria:

    • Clinical and/or radiographic evidence of residual or persistent breast cancer

    • Receiving immunosuppressive therapy to include methotrexate or steroids (note: the use of prednisone, or equivalent, <2.0mg/day, is allowed)

    • Tbili >1.8, creatinin >2, hemoglobin <10, platelets <100,000/mm³, WBC <2,000

    • Active pulmonary disease requiring medication to include multiple inhalers

    • Patients may not be receiving any other investigational agents (except with permission of the Lead Principal Investigator)

    • Pregnant or are nursing

    • History of autoimmune disease (patients with vitiligo not excluded)

    • HIV positive

    • Previous or concomitant malignancies at other sites, except effectively treated non- melanoma skin cancers or carcinoma in situ of the cervix or effectively treated malignancy that has been in remission for over 5 years and highly likely to have been cured

    • Other concurrent severe medical problems, unrelated to the malignancy, that would significantly limit full compliance with the study or expose the patient to unacceptable risk

    • Uncontrolled congestive heart failure or hypertension, unstable heart disease (coronary artery disease or myocardial infarction) or uncontrolled arrhythmia at the time of enrollment

    • Psychiatric, addictive, or any disorder which compromises ability to give truly informed consent for participation in this study or adequate compliance

    Contacts and Locations

    Locations

    No locations specified.

    Sponsors and Collaborators

    • Cancer Insight, LLC

    Investigators

    • Principal Investigator: George E Peoples, MD, Cancer Insight

    Study Documents (Full-Text)

    None provided.

    More Information

    Publications

    None provided.
    Responsible Party:
    George E. Peoples, CEO/Founder, Cancer Insight, LLC
    ClinicalTrials.gov Identifier:
    NCT03014076
    Other Study ID Numbers:
    • C.2008.146
    First Posted:
    Jan 9, 2017
    Last Update Posted:
    Jan 9, 2017
    Last Verified:
    Jan 1, 2017
    Individual Participant Data (IPD) Sharing Statement:
    No
    Plan to Share IPD:
    No
    Additional relevant MeSH terms:
    Breast Neoplasms
    Trastuzumab

    Study Results

    No Results Posted as of Jan 9, 2017